Striatal calcium channel antagonist receptors in huntington's disease and parkinson's disease
- 1 March 1988
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 23 (3) , 303-305
- https://doi.org/10.1002/ana.410230316
Abstract
The density of calcium channel antagonist receptors labeled by (+)‐[3H]PN 200‐110 was reduced by 75% in striata from patients with Huntington's disease, but unchanged in patients with Parkinson's disease, compared with control subjects. These receptors are therefore likely to be localized to neurons with cell bodies in striatum, rather than nigrostriatal nerve terminals or glia, and their loss may contribute to the pathophysiology of basal ganglia disorders.This publication has 13 references indexed in Scilit:
- Calcium channels and calcium channel antagonistsAnnals of Neurology, 1987
- DILTIAZEM FOR TARDIVE DYSKINESIAThe Lancet, 1987
- Evidence for a Selective Localization of Voltage-Sensitive Ca2+Channels in Nerve Cell Bodies of Corpus StriatumJournal of Neurochemistry, 1986
- PARKINSONISM, TARDIVE DYSKINESIA, AKATHISIA, AND DEPRESSION INDUCED BY FLUNARIZINEThe Lancet, 1986
- Characterization of binding sites for two classes of calcium channel antagonists in human forebrainEuropean Journal of Pharmacology, 1985
- The effects of dihydropyridines of neurotransmitter release from cultured neuronal cellsLife Sciences, 1984
- Diltiazem and AkathisiaAnnals of Internal Medicine, 1983
- The effects of lesions in the rat hippocampus suggest the association of calcium channel blocker binding sites with specific neuronal populationNeuroscience Letters, 1983
- Calcium channel antagonist binding sites labeled by 3H-nimodipine in human brainJournal of Neurosurgery, 1983
- Neurotransmitter receptor alterations in Parkinson's diseaseLife Sciences, 1977